Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | PHASE2 | RECRUITING | 140 | — | — | Oct 21, 2025 | Dec 31, 2028 | Apr 14, 2026 | 11 | Canada |
| Arm | Type | Description |
|---|---|---|
| STRIDE (durvalumab + tremelimumab) | ACTIVE_COMPARATOR | - |
| STRIDE (durvalumab + tremelimumab) + Lenvatinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| STRIDE (durvalumab + tremelimumab) | DRUG | As first treatment |
| Durvalumab | DRUG | monotherapy every 4 weeks |
| Lenvatinib | DRUG | Daily |
Inclusion Criteria: * Age ≥ 18 years. * Body weight \> 30 kg. * Life expectancy of at least 12 weeks. * Confirmed HCC based on histopathological findings from tumour tissues or clinically by AASLD criteria in cirrhotic participants. * Must not have received prior systemic therapy for HCC. * Must no...